Developments in Cardiovascular Medicine

1. What's new in cardiac imaging?.- 2. Why new cardiac imaging agents?.- Section one: Perfusion.- 3. The value of measuring myocardial perfusion in coronary artery disease.- Single photon imaging.- 4. Myocardial perfusion imaging with xenon-133.- 5. Myocardial perfusion and krypton-81m.- 6. Myocardial perfusion imaging with technetium-99m isonitriles; attractive thallium substitutes?.- 7. Is there a specific role for technetium-99m SestaMIBI in the assessment of cardiac arrhythmias?.- 8. Technetium-99m complexes of functionalized diphosphines for myocardial perfusion imaging in man.- 9. Myocardial perfusion imaging with technetium-99m teboroxime.- Positron emission tomography.- 10. Clinical applications of rubidium-82 myocardial perfusion imaging.- 11. Nitrogen-13 ammonia perfusion imaging.- 12. Quantification of myocardial perfusion with oxygen-15 water.- 13. Myocardial perfusion imaging with copper-62 labeled Cu-PTSM.- Magnetic resonance imaging.- 14. Application of contrast agents in magnetic resonance imaging: additional value for detection of myocardial ischemia?.- 15. Magnetic resonance imaging using paramagnetic contrast agents in the clinical evaluation of myocardial infarction.- Section two: Metabolism.- 16. Assessment of myocardial metabolism in vivo. a biochemist' view.- Single photon imaging.- 17. Myocardial metabolic imaging with iodine-123 fatty acids.- Positron emission tomography.- 18. Assessment of myocardial fatty acid metabolism with carbon-11 palmitate.- 19. Myocardial metabolic imaging with fluorine-18 deoxyglucose.- 20. Myocardial metabolic imaging with carbon-11-acetate.- Section three: Infarct-avid imaging.- Single photon imaging.- 21. Infarct-avid imaging: usefulness, problems and limitations.- 22. Myocyte necrosis-avid with radiolabeled antimyosin antibody: experimental and clinical acute myocardial infarction, myocarditis and heart transplant rejection.- 23. Myocardial infarct imaging with cardiac troponin-I antibodies.- Section four: Function.- Single photon imaging, positron emission tomography.- 24. Radionuclide imaging in the evaluation of cardiac function: new developments?.- Single photon imaging.- 25. Krypton-81m equilibrium radionuclide ventriculography for the assessment of right ventricular function.- 26. Simultaneous assessment of myocardial function and perfusion.- Section five: Sympathetic nerve system.- Single photon imaging.- 27. Radiolabeled metaiodobenzylguanidine (1-123 MIBG): value in clinical cardiology?.- 28. Scintigraphic assessment of cardiac innervation using iodine-123 metaiodobenzylguanidine.- 29. Clinical experience with iodine-123 metaiodobenzylguanidine.- Positron emission tomography.- 30. Studies of cardiac receptors by positron emission tomography.- 31. Heart neuronal imaging with carbon-11- and fluorine-18-labeled tracers.- Section six: Leukocytes, platelets, lipoproteins.- Single photon imaging.- 32. Labeling of leukocytes, platelets, and lipoproteins: useful in clinical cardiology?.- 33. Indium-111 leukocyte scintigraphy for detection of valvular abscesses and vegetations.- 34. Detection of cardiac thrombi with indium-111 platelet scintigraphy.- 35. Scintigraphic detection of atherosclerosis with radiolabeled low density lipoprotein.- Section seven: Viability.- Single photon imaging, positron emission tomography, magnetic resonance imaging.- 36. Assessment of myocardial viability with scintigraphic techniques and magnetic resonance imaging: new attainments?.- Positron emission tomography.- 37. Is it worth assessing regional myocardial viability with positron emission tomography?.- 38. Assessment of tissue viability after myocardial infarction with fluorine-18 deoxyglucose using planar imaging; the alternative approach.- Section eight: Alternative stress imaging.- Single photon imaging, echocardiography, magnetic resonance imaging.- 39. New developments in pharmacological stress imaging.